Abstract: FR-PO0501
Is Angiotensin Receptor-Neprilysin Inhibitor (ARNI) the Magic Wand? A Single-Centre, Double-Blind, Randomised, Active-Controlled Study to Evaluate the Efficacy and Safety of ARNI vs. ARB in Patients with CKD and Heart Failure on Maintenance Hemodialysis (MHD)
Session Information
- CKM: Clinical - Trials, Epidemiology, and Biomarkers
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Maulik, Bibek, Institute of Postgraduate Medical Education and Research, Kolkata, WB, India
- Pal, Atanu, Institute of Postgraduate Medical Education and Research, Kolkata, WB, India
- Das, Arabinda, Acharya Prafulla Chandra College, Kolkata, WB, India
- Lohia, Priyangani, Institute of Postgraduate Medical Education and Research, Kolkata, WB, India
- Mahapatra, Rima, Institute of Postgraduate Medical Education and Research, Kolkata, WB, India
Background
Patients with stage 5 chronic kidney disease on maintenance hemodialysis often suffer from heart failure with reduced ejection fraction. Sacubitril / Valsartan ( ARNI ) has shown benefits in heart failure , but it's efficacy and safety in this population remain under explored
Methods
This was a hospital based ,single centre ,randomised prospective study comparing sacubitril valsartan with Telmisartan in 88 adults patients with stage 5 ckd on MHD and EF<50%. Patients were followed for 6 months and outcomes including EF, NYHA class were evaluated
Results
The sample size of 88 with 44 in each arm is sufficient to detect clinically important difference between two groups with effect size 0.3, error probability at 0.05 and power at 0.95 was determined using repeated measures ANOVA in Gpower. No significant difference found in mean age between two groups (p value >0.01). Gender is not associated with treatment arms. Average Hd vintage is insignificant between groups. SBP And DBP show no significant difference in mean values between groups. Treatment is significantly related to EF and a significant improvement was found in mean EF among participants with ARNI at the end of 6 months ( p value <0.01). Significant increment was seen at the end of 6 months compared to baseline. No significant difference found for mean potassium level between groups. Treatment was significantly related to NYHA ( p value < 0.01 ) and ARB associated with higher category in NYHA compared to ARNI
Conclusion
Treatment is significantly related to EF and a significant improvement was found in mean EF among participants with ARNI at the end of 6 months ( p value <0.01) . Treatment was significantly related to NYHA (p value <0.01). ARNI appears to be superior to ARB therapy in improving cardiac function and clinical symptoms in patents with advanced CKD on HD and HFrEF
Funding
- Government Support – Non-U.S.